Our Clinical Trial Portfolio

Advancing Healthcare Through Innovative Clinical Research. Ardent Clinical Research Services has successfully conducted a diverse range of clinical trials across therapeutic areas including oncology, metabolic disorders, vaccines, urology, hepatology, phytopharmaceuticals, COVID-19, and more. Here is a snapshot of our active, completed, and regulatory-submitted trials:

Image
🔬

Metabolic & Endocrine Disorders

•Semaglutide Injection – Type 2 Diabetes Mellitus (T2DM)
•Dapagliflozin + Vildagliptin + Metformin – Phase IV (T2DM)
•Fixed Dose Combination of DAPA + Gliclazide – T2DM (Product approved – Nov 2023)
•Vildagliptin + Pioglitazone Hydrochloride Tablets (50/15 mg) – Approved by DCGI (2022)
•Remogliflozin vs. Dapagliflozin – Glycemic Variability (REMIT-GV Study)
•Teneligliptin – TIR Metric using CGM (TOP-TIR Study)
•Type 2 Diabetes – 2 Trials with Gymne Mag-D
💉

Injectables & Drug Delivery Systems

  • Ondansetron 100 mg Injection – Phase III Study
  • Needle-Free Injection System Trials:
  • HPV (Cervavac Vaccine)
  • MMR (Tresivac Vaccine)
  • Hexavalent Vaccines
  • All PMS Vaccines for infants aged below 6 months & 6–24 months
🧬

Oncology

NUVASTATIC – 4 Studies for Breast & Colon Cancer

Capecitabine 500 mg – For EMEA and MHRA submission

Chemotherapy-Induced Fatigue:

In TNBC patients using NUVASTATIC (Phytopharmaceuticals)

In Colorectal Cancer patients using NUVASTATIC

FCM (Ferric Carboxymaltose) – 196 patients (EMEA submission)

🧠

Urology & Men's Health

Silodosin + Solifenacin – Phase III (BPH)

Benign Prostate Hyperplasia – With Pro-Plus (Publication under review)

Oligospermia – 2 Trials using CoQ-10

🫀

Cardiology & Hypertension

  • Telmisartan 40 mg vs. Cilnidipine 10 mg – ABPM Study for 24-hour effect
🧪

Liver Disorders & Hepatology

•Nor-UDCA – For NASH (Under regulatory approval)
•No-UDCA – For NAFLD (Completed IND Approval received)
•Polyherbal Formulations – For NAFLD (Completed and under publication)
•Non-Alcoholic Fatty Liver Disease – (Completed)
🌿

Phytopharmaceuticals & Herbal Studies

  • Ashwagandha (DSTR) – Moderate Stress Management
  • Yeshtimadhu (AYUSH – COVID-19) – Completed
  • Gudichipipali (AYUSH – COVID-19) – Completed
  • COVID-19 Antiviral (Patented Herbal Product) – Completed & submitted to AYUSH
  • OBINIL – Obesity Management
  • Ashwagandha, Amaranthus – BE Studies – Completed
  • Canker Sore Gingivitis – Completed
  • Herbal Cough Syrup (Russian Product) – Completed
  • Metabolic Syndrome Study – Completed
🦠

COVID-19 Clinical Trials

•MOLNUPIRAVIR – Study with 1218 patients (Sponsor: MSN Laboratories)
•Proof of Concept Study – Long-term antibody sustainability (Under publication)
•CSIR-IIIM/AYUSH Ministry Trials – 2 COVID-19 Phase II Trials awarded
•COVID-19 Antiviral Phase I & Phase I Clinical Trials – In Mild to Moderate Patients
•COVID-19 (Ketone Bodies) – Completed (Under Publication)
🩺

Other Therapeutic Areas

Gut Health in CKD with Diabetes – (Under publication)

Needle-Free Vaccination Trials – For multiple age groups and vaccine types

OMEGA-3 BE Study – Completed